



Aducanumab for Alzheimer’s Disease

Draft Questions for Deliberation and Voting: July 15, 2021 Public Meeting

These questions are intended for the deliberation of the CTAF voting body at the public meeting.

Patient population for all questions: *Adults with early Alzheimer’s disease (i.e., mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease dementia) who are initiating therapy.*

Clinical Evidence

1. Is the available evidence adequate to demonstrate that the net health benefit of aducanumab plus supportive care is superior to that provided by supportive care alone?

Yes

No

Contextual Considerations and Potential Other Benefits or Disadvantages

Please vote on the following contextual considerations relevant for Alzheimer’s disease:

When making judgments of overall long-term value for money, what is the relative priority that should be given to any effective treatment for Alzheimer’s disease, on the basis of the following contextual considerations:

1 = Very low priority; 2 = Low priority; 3 = Average priority; 4 = High priority; 5 = Very high priority

2. Acuity of need for treatment of individual patients based on the severity of the condition being treated
3. Magnitude of the lifetime impact on individual patients of the condition being treated
4. Other (as relevant):

Please vote on the following potential other benefits or disadvantages relevant for aducanumab:

What are the relative effects of aducanumab plus supportive care versus supportive care alone on the following outcomes that inform judgment of the overall long-term value for money of aducanumab?

1 = Major negative effect; 2 = Minor negative effect; 3 = No difference; 4 = Minor positive effect; 5 = Major positive effect

5. Patients' ability to achieve major life goals related to education, work, or family life
6. Caregivers' quality of life and/or ability to achieve major life goals related to education, work, or family life
7. Patients' ability to manage and sustain treatment given the complexity of regimen
8. Health inequities
9. Other (as relevant)

Long-Term Value for Money

10. Given the available evidence on comparative effectiveness and incremental cost effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment at assumed pricing with aducanumab plus supportive care versus supportive care alone
 - a. Low long-term value for money at assumed price
 - b. Intermediate long-term value for money at assumed price
 - c. High long-term value for money at assumed price